Pharmacokinetics and safety of LB80380, LB80920 and LB80331 after oral Administration of LB80380 in Healthy Male Volunteers |
Kim, Sung-Eun
(Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital)
Shin, Kwang-Hee (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Kim, Tae-Eun (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Lee, Seung-Hawn (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Kim, Bo-Hyung (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Kim, Min-Jeong (Department of Clinical Development, LG Life Sciences, Ltd) Yoon, Seo-Hyun (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Cho, Joo-Youn (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Shin, Sang-Goo (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Jang, In-Jin (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) Yu, Kyung-Sang (Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital) |
1 | LB80380, Investigator's Brochure, LG life sciences, LTD. |
2 | Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrob Agents Chemother, 2009;53(5): 1779-1785. DOI ScienceOn |
3 | Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed, Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 1995;250-252. |
4 | Lok AS and McMahon BJ. The AASLD Practice Guidelines. Chronic Hepatitis B: Update 2009. Available from:http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice% 20 Guidelines/Chronic_Hep_B_Update_2009;208_24_2009.pdf |
5 | Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dosefinding study of oral LB80380 in HBeAgpositive patients with chronic hepatitis B, Antivir Ther, 2006;11(8):977-983. |
6 | Lai CL, Han KH, Yoon SK, Um SH, Yuen MF, Kim HS, Kim HR, Chung HC, Kim CR, Hysu P, Averett D, Worland S, Kim J. Phase II, multi-centre, dose-escalating study of LB80380(ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV. J Hepatol, 2006;44(S2):S5. |
7 | Liaw YF, Chu CM, Hepatitis B virus infection. Lancet, 2009;373:582-592. DOI ScienceOn |
8 | World Health Organization. Hepatitis B. Available from: http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf |
9 | Jae Youn Cheong. Management of Chronic Hepatitis B in Treatment-Naive Patients. Kor J Gastroenterol, 2008;51:338-345.(Korean) |
10 | Fung SK, Lok AS. Hepatitis B Virus Genotypes: Do They Play a Role in the Outcome of HBV Infection? Hepatology, 2004;40(4):790-792. DOI |